Phase 3 (P3) study of quizartinib (Q) or placebo (P) with induction (IND) and consolidation chemotherapy (CON) and as maintenance (MN) in patients (pts) with newly diagnosed (NDx) FLT3-ITD–positive acute myeloid leukemia (AML): the QuANTUM-First study.


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Erba, HP; Levis, MJ; Sekeres, MA; Dombret, H; Amadori, S; Zernovak, O; Mires, DE; Ge, N; Hanyok, J; Macintyre, S; Gokmen, S; Gammon, G; Schlenk, RF

Published Date

  • May 20, 2016

Published In

Volume / Issue

  • 34 / 15_suppl

Start / End Page

  • TPS7073 - TPS7073

Published By

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Digital Object Identifier (DOI)

  • 10.1200/jco.2016.34.15_suppl.tps7073